Dihexa vs Semax
Angiotensin IV Analog · ACTH Fragment
Here is how these two compounds compare, based on published research, not marketing claims.
Dihexa
Promotes synaptogenesis through HGF/MET signaling with compelling laboratory potency data; zero published human clinical trials.
Semax
Increases brain-derived growth factors for cognitive enhancement and neuroprotection; approved in Russia with published human data.
Dihexa
11 studies
0 human trials
Not FDA-Approved
Semax
204 studies
10 human trials
Not FDA-Approved
What it does
Dihexa
Promotes the formation of new synaptic connections in the brain through hepatocyte growth factor (HGF) signaling. Reported in laboratory studies as a potent driver of synaptogenesis, the process by which brain cells form new communication pathways.
Semax
Increases brain-derived growth factors (BDNF and NGF) to support cognitive function, memory, and neuroprotection. Derived from a fragment of ACTH but engineered to have zero hormonal activity.
How it works
Dihexa
Dihexa is a synthetic analog of angiotensin IV developed at Washington State University. It binds to and activates the hepatocyte growth factor (HGF) receptor (also called MET), which drives synaptogenesis and dendritic spine formation in brain tissue. In laboratory studies, the Harding research group reported that dihexa promoted synaptic connections at concentrations far lower than BDNF in cell culture models. The mechanism operates through MET receptor signaling rather than the conventional neurotrophin pathway, representing a pharmacologically distinct approach to synaptic plasticity.
Semax
Semax is a synthetic heptapeptide based on the ACTH (4-10) fragment with a Pro-Gly-Pro C-terminal extension that eliminates the adrenal hormonal effects of ACTH while preserving and enhancing the neuroprotective properties. It upregulates BDNF (brain-derived neurotrophic factor) and NGF (nerve growth factor), two growth factors that drive synaptic plasticity, neuronal survival, and memory consolidation. Semax also modulates dopaminergic and serotonergic neurotransmission, contributing to attention and mood regulation.
How often
Dihexa
No standardized dosing protocol exists. Dihexa has been studied in animal models (rats) for cognitive effects. No human clinical trials have been published. The compound is available in research peptide markets but has no regulatory status in any country.
Semax
In Russian clinical practice, Semax is administered as a nasal spray for cognitive enhancement and stroke recovery. The compound received Russian regulatory approval. No FDA-approved product exists. Research protocols outside Russia primarily use nasal administration.
How strong
Dihexa
The in vitro synaptogenesis data from the Harding lab is compelling at the mechanistic level. Animal studies showed improved cognitive performance in aged rats. The HGF/MET pathway approach is pharmacologically distinct from traditional nootropics. However, zero published human data exists. The gap between laboratory potency and clinical validation is the defining feature of this compound's evidence profile.
Semax
Russian regulatory approval for nootropic and neuroprotective indications including stroke recovery. Published human studies document BDNF elevation, cognitive improvements, and neuroprotective effects in ischemic stroke patients. The compound has both preventive (cognitive support) and therapeutic (neuroprotection after injury) research applications.
Main tradeoff
Dihexa
The most potent synaptogenesis enhancer in laboratory studies has zero published human clinical data. Dihexa is widely sold as a research peptide based on a small body of academic research from a single laboratory. No independent replication of the core findings has been published. No human safety data exists. The compound has not entered any clinical trial program. The distance between the laboratory data and clinical use is the largest of any widely-sold nootropic peptide.
Semax
Same geographic evidence concentration as Selank: Russian regulatory approval with limited Western clinical replication. The BDNF and NGF elevation mechanisms are well-characterized, but controlled Western clinical trials are absent. Available through research peptide markets; not through standard Western clinical channels. Not FDA-approved for any indication.
Best for
Dihexa
- Research on HGF/MET receptor signaling as a synaptogenesis pathway distinct from BDNF
- Research on angiotensin IV analogs and their cognitive effects in animal models
- Research evaluating the gap between in vitro potency and clinical translation in nootropic development
Semax
- Research on BDNF and NGF upregulation as a neuroprotective and nootropic strategy
- Research on ACTH-derived peptides engineered to separate neuroprotective from hormonal effects
- Research on peptide-based cognitive enhancement and post-stroke neuroprotection
How to choose
A good fit for Dihexa
- Research on HGF/MET signaling as a synaptogenesis pathway distinct from neurotrophin-based approaches
- Research on angiotensin IV analogs and their cognitive effects in animal models
- Research evaluating preclinical-to-clinical translation gaps in nootropic development
A good fit for Semax
- Research on BDNF/NGF upregulation with human clinical evidence
- Research contexts where regulatory approval and human safety data carry weight
- Research on defined nootropic mechanisms with published clinical validation
Consider both across time
Dihexa and Semax illustrate the gap between laboratory potency and clinical evidence. Dihexa has compelling in vitro synaptogenesis data from the Harding lab but has never been tested in human clinical trials. Semax has more modest mechanistic claims but years of human clinical use in Russia. For research questions about HGF/MET-driven synaptogenesis, Dihexa is the relevant compound. For research questions about clinically validated nootropic peptides, Semax has the evidence.
Dosing should be determined by a qualified physician who can evaluate individual circumstances. PSI does not provide personalized dosing guidance.
Official dosing references
- DailyMed(NIH drug labels)
- ClinicalTrials.gov
- PubMed
For readers who want the biology: here is the pathway each compound uses to signal the body. This section is optional. The comparison above covers the practical differences.
▶See the biology
- HGF Receptor Binding
- HGF Receptor Binding activates MET Signaling Activation
- MET Signaling Activation drives Synaptogenesis
- Synaptogenesis connects to Dendritic Spine Formation
- Synaptic Density Increase connects to Cognitive Enhancement
- Dendritic Spine Formation connects to Synaptic Density Increase
- BDNF Upregulation
- NGF Upregulation
- BDNF Upregulation modulates Dopaminergic Modulation
- BDNF Upregulation drives Synaptic Plasticity Enhancement; NGF Upregulation enables Synaptic Plasticity Enhancement
- Synaptic Plasticity Enhancement connects to Cognitive Function Support; Dopaminergic Modulation connects to Cognitive Function Support
- BDNF Upregulation supports Neuroprotection; NGF Upregulation supports Neuroprotection
Dihexa activates the HGF/MET receptor pathway to drive synaptogenesis and dendritic spine formation in brain tissue.
Semax upregulates BDNF and NGF in the brain, driving synaptic plasticity and neuroprotection.
Research Evidence
Semax has substantially more clinical evidence: Russian regulatory approval, published human studies in stroke recovery and cognitive enhancement. Dihexa has a small body of published preclinical research from the Harding laboratory at Washington State University, with animal cognitive studies and in vitro synaptogenesis data. No independent replication of the core Dihexa findings has been published. The evidence gap is large and structural.
- 1.
For evidence-based cognitive support, semax has regulatory approval and clinical history.
- 2.
For theoretical interest in synaptogenesis, dihexa's animal data is fascinating but unvalidated.
- 3.
For any practical use, semax is the only option with human experience.
- 4.
For research interest in next-generation nootropics, dihexa represents an intriguing but unproven concept.
Key Limitations
- •The evidence gap makes meaningful clinical comparison impossible.
- •Dihexa has no human data whatsoever.
- •Semax's evidence base is concentrated in Russian literature.
- •Neither is FDA-approved.
Community Discussion
PSI monitors discussions across peptide research and biohacking communities. These are reported experiences, not clinical evidence.
Dihexa
"Dihexa is millions of times more potent than BDNF"
Technically accurate but misleading
"Dihexa is the strongest nootropic available"
Insufficient evidence
"I'm worried about dihexa and cancer risk"
Legitimate concern
Semax
"Semax improved my focus and cognitive performance"
Plausible but unproven
"It helped with my brain fog after COVID"
Anecdotal only
"The nasal version works within minutes"
Plausible but unproven
Safety Comparison
Semax has published human safety data from Russian clinical use with no significant adverse effects reported. Dihexa has no published human safety data. The compound's effects on HGF/MET signaling raise theoretical concerns about cell proliferation that have not been assessed in any human safety study. The safety comparison is defined by the absence of data for Dihexa rather than the presence of concerning signals.
Dihexa
No human safety data exists. Animal toxicology is limited. The compound is very potent, which raises theoretical concerns about uncontrolled growth factor signaling.
Semax
Approved in Russia. Decades of clinical use. Reported as well-tolerated via intranasal administration. Limited Western safety data.
What the Research Suggests
Semax is the evidence-based option. Dihexa is the speculative one. If the question is what to actually use, semax has clinical backing. If the question is what might matter in the future, dihexa's animal data is striking, but striking animal data has failed to translate to humans countless times in neuroscience.